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Abstract 40 
Using Eudragit E PO (EudrE) as polymethacrylate carrier, the aim of the study was to 41 
develop a pH-independent dosage form containing ibuprofen (IBP) as active compound via 42 
chemical modification of the polymer (i.e. quaternisation of amine function) or via the addition 43 
of dicarboxylic acids (succinic, glutaric and adipic acid) to create a pH micro-environment 44 
during dissolution. Biconvex tablets (diameter: 10mm; height: 5mm) were produced via hot 45 
melt extrusion (HME) and injection molding (IM). In vitro dissolution experiments revealed 46 
that a minimum of 25% of quaternization was sufficient to partially (up to pH 5) eliminate the 47 
pH-dependent effect of the EudrE/IBP formulation. The addition of dicarboxylic acids did not 48 
alter IBP release in a pH 1 and 3 medium as the dimethyl amino groups of EudrE are already 49 
fully protonated, while in a pH 5 solvent IBP release was significantly improved (cf. from 0 to 50 
92% release after 1h dissolution experiments upon the addition of 20wt.% succinic acid). 51 
Hence, both approaches resulted in a pH-independent (up to pH 5) immediate release 52 
formulation. However, the presence of a positively charged polymer induced stability issues 53 
(recrystallization of API) and the formulations containing dicarboxylic acids were classified as 54 
mechanically unstable. Hence, further research is needed to obtain a pH-independent immediate 55 
release formulation while using EudrE as polmethacrylate carrier. 56 
  57 
Introduction 58 
Hot melt extrusion (HME) combined with injection molding (IM) is a versatile 59 
manufacturing technique which has generated significant interest in the pharmaceutical field 60 
based on the possibilities offered by this technique (Crowley et al., 2007, Repka et al., 2007, 61 
Follonier et al., 1994, Repka et al., 1999). It enables the production of tablets independent of 62 
the powders compactibility (Quinten et al., 2011). A homogeneous system can be created via a 63 
substantial energy input, provided by elevated temperature, high shear force and pressure. 64 
Different polymers are used as matrix drug delivery systems, wherein the drug is uniformly 65 
dispersed or dissolved (providing immediate or sustained drug release depending on the 66 
polymer properties) (Yang et al., 2008, Zhang and McGinity, 2000, Repka et al., 2003, Jijun et 67 
al., 2011, Zhu et al., 2006, Maniruzzaman et al., 2013). A well established drug delivery matrix 68 
which can be used for HME/IM applications is a methacrylate terpolymer based on n-69 
butylmethacrylate (n-BMA), dimethylaminoethylmethacrylate (DMAEMA) and 70 
methylmethacrylate (MMA) in a 1/2/1.5-ratio (Eudragit® E PO) (Albers et al., 2009, Albers and 71 
Kleinebudde, 2008, Claeys et al., 2013, Qi et al., 2008, Six et al., 2003, Liu et al., 2010). It 72 
allows the development of stable glassy solid solutions, i.e. homogeneous one-phase systems 73 
with the drug molecularly dispersed in the matrix, ensuring immediate drug release (Albers et 74 
al., 2009, Claeys et al., 2013, Forster et al., 2001). However, the pH-dependent solubility of 75 
Eudragit E (i.e. insoluble at high pH, soluble at low pH) could possibly cause bioavailability 76 
problems when dealing with elderly (Russell et al., 1993, Riordan et al., 1997), upon food intake 77 
(Kararli, 1995) or diseases that tend to raise the stomach pH (Theisen et al., 2000, Williams and 78 
McColl, 2006).  79 
In vitro dissolution studies of nimodipine, for instance, in a medium containing 0.1N 80 
hydrochloric acid and 0.05% (w/v) sodium dodecyl sulfate (SDS) showed that a solid dispersion 81 
with EudrE dissolved significantly faster than formulations with polyvinylpyrrolidone/vinyl 82 
acetate copolymer (PVPVA) and hydroxypropyl methylcellulose (HPMC) as polymer 83 
excipient. In vivo studies in male beagle dogs, on the other hand, revealed the fastest release for 84 
the formulation containing PVPVA as polymer excipient, followed by EudrE and HPMC 85 
(Zheng et al., 2007). This difference between in-vitro and in-vivo behavior could be due to the 86 
GI motility of a beagle dog which is among the fastest of all laboratory animal (fast stomach 87 
clearance), to the limited volume of gastric fluids (± 400mL) and most importantly to the gastric 88 
pH of the dogs which can reach pH 5 (Kararli, 1995). EudrE is also used as coating material for 89 
pH-controlled drug release in the treatment of inflammatory bowel disease (Leopold and 90 
Eikeler, 1998). Lag times of drug release for EudrE-coated formulations were determined at 91 
10min, 50min and 33h in media with pH values of 2, 5 and 6.8, respectively. The pH-dependent 92 
release profile of Eudragit E is due to its dimethylaminoethyl methacrylate (DMAEMA) moiety 93 
which becomes protonated at low pH values. Moreover, as shown in previous work (Claeys et 94 
al., 2013), the DMAEMA units are crucial with respect to API/polymer interaction (which are 95 
essential to create glassy solid solutions) and drug release characteristics. 96 
 97 
This research focuses on the development of a pH-independent Eudragit E-based 98 
formulation, using 2 approaches to achieve pH-independent ibuprofen release from an Eudragit 99 
E matrix processed via HME/IM: 1. chemical modification of the Eudragit polymer structure 100 
by quaternization of the amine function; 2. creation of a low pH microenvironment during 101 
dissolution via the addition of dicarboxylic acids (succinic, glutaric and adipic acid). 102 
Experimental Section  103 
Materials 104 
Ibuprofen 25 (IBP), with a melting endotherm at 76°C and a Tg of -42°C, was purchased 105 
from Abbott (Ludwigshafen, Germany). Eudragit® E PO (EudrE), a methacrylate terpolymer 106 
based on n-butylmethacrylate (n-BMA), dimethylaminoethylmethacrylate (DMAEMA) and 107 
methylmethacrylate (MMA) in a 1/2/1.5-ratio, was supplied by Evonik (Darmstadt, Germany). 108 
Diethylether and acetic acid were purchased by Biosolve (Valkenswaard, Netherland), 109 
hydrochloric acid from VWR International (Leuven, Belgium). Iodomethane, silver nitrate and 110 
dicarboxylic acids (succinic, glutaric and adipic acid) were purchased from Sigma-Aldrich (St-111 
Louis, USA) (Table 1).  112 
Table 1: Chemical characteristics of dicarboxylic acids 113 
Dicarboxylic 
acid 
COOH 
-R- 
COOH 
pKa1 pKa2 Tm 
(°C) 
Solubility 
in H2O 
(g/L) at 
25°C 
logP 
Succinic 
Glutaric 
Adipic 
CH2CH2 
 (CH2)3 
(CH2)4 
4.2 
4.3 
4.4 
5.6 
5.4 
5.4 
184 
95 
152 
60 
430 
24 
-0.59 
-0.29 
0.08 
 114 
Quaternization of Eudragit® E PO 115 
Eudragit® E PO (20g) was dissolved in 200mL methanol (final concentration: 116 
100mg/mL), followed by the addition of 0.41, 1.02, 2.03 and 3.05mL iodomethane (methylating 117 
agent) to synthesize polymethacrylates with a quaternization degree of 10, 25, 50 and 75%, 118 
respectively. The reaction (addition of methylgroup to the polymer structure) was allowed to 119 
proceed for 2h at room temperature, followed by precipitation of the polymer via the addition 120 
of diethylether (1/20, v/v). Consequently, the iodide counter ion of the quaternary amine was 121 
replaced by chloride via dialysis (using a cellulose dialysis membrane with a Mw cut-off of 14 122 
kDa) for 2 days against a 60g/L aqueous sodium chloride solution, which was refreshed 123 
multiple times. The removal of iodide ions was verified via the addition of a silver nitrate 124 
solution as described in previous research (Obermeier et al., 2010). Finally, the quaternized 125 
Eudragit® E polymer (EudrE-Q) was isolated as a dry powder by lyophilization (average yield: 126 
70%).  127 
1H-Nuclear Magnetic Resonance (1H-NMR) Spectroscopy 128 
Polymer composition and degree of quaternization was determined through 1H-NMR 129 
spectroscopy on a Varian Mercury 300 NMR Spectrometer (Vernon Hills, Illinois, USA). 130 
Samples were dissolved in deuterated methanol. 1H-NMR (300 MHz, CD3OD) δ = 4.12 (br, 131 
COOCH2CH2N(CH3)2), 3.64 (COOCH3), 2.68 (br, COOCH2CH2N(CH3)2), 2.35 (br, 132 
COOCH2CH2N(CH3)2), 2.21-1.75 (br, CH2 backbone), 1.45 (br, COOC(CH3)3, 1.30-0.8 (br, 133 
CH3). The degree of quaternization was verified according to Obermeier et al. (Obermeier et 134 
al., 2010).  135 
Determination of pKa  136 
A polymer sample (200mg) was dissolved in 5mL 0.1M HCl solution, followed by the 137 
addition of 45mL demineralized water. While continuously measuring the pH, small amounts 138 
of 0.1M NaOH were added to the polymer solution up to pH 12. Consequently, the pKa was 139 
determined as a minimum of the first derivative of the titration cruve.   140 
 141 
Thermal analysis 142 
Thermogravimetric analysis (TGA 2950, TA instruments, Leatherhead, UK) was used 143 
to investigate the thermal stability of the polymers. The samples were equilibrated at 30°C and 144 
heated (10°C/min) to 500°C under an N2 atmosphere.  145 
Tg and melting point (Tm) of pure components, physical mixtures (homogenized using 146 
mortar and pestle) and injection molded tablets were analyzed by modulated differential 147 
scanning calorimetry (MDSC Q2000, TA Instruments, Leatherhead, UK) using a heating rate 148 
of 2°C/min.  The modulation period and amplitude were set at 1min and ±0.318°C, respectively. 149 
Dry nitrogen at a flow rate of 50ml/min was used to purge the MDSC cell. A heating/cool/heat 150 
cycle was run between -70 and 120°C. All results were analyzed using the TA Instruments 151 
Universal Analysis 2000 software.  152 
X-ray diffraction (XRD) 153 
The crystallinity of the samples was determined via X-ray diffraction using a D5000 Cu 154 
Kα diffractor (λ = 0.154 nm) (Siemens, Karlsruhe, Germany) with a voltage of 40 kV and a 155 
current of 40 mA in the angular range of 10° < 2θ < 60° using a step scan mode (step width = 156 
0.02°, counting time = 1 s/step). 157 
Production of injection molded tablets 158 
Physical mixtures of IBP and polymer (30/70, wt.%) were extruded at 90°C using a co-159 
rotating twin-screw extruder at 90rpm (Haake MiniLab II Micro Compounder, Thermo 160 
Electron, Karslruhe, Germany). Biconvex tablets (mass: 349 ± 2.1mg; diameter: 10mm; height: 161 
5mm) were produced via injection molding (Haake MiniJet System, Thermo Electron). The 162 
injection pressure was 800bar during 10s, in combination with a post-pressure of 400bar for 5s. 163 
Formulations containing dicarboxylic acids were processed via HME/IM at a constant drug load 164 
(30%), but varying ratios of Eudragit E to dicarboxylic acid: 60/10, 55/15 and 50/20 (wt.%). 165 
In vitro drug release 166 
Drug release from the injection molded tablets was determined using the paddle method 167 
on a VK 7010 dissolution system (VanKel Industies, New Jersey, USA) with a paddle speed of 168 
100rpm. Hydrochloric acid (pH 1), citric buffer (pH 3 and 5) and phosphate buffer ( pH 7) were 169 
used as dissolution media (900mL) at 37 ± 0.5°C. Samples were withdrawn at 5, 10, 15, 20, 30, 170 
45 and 60min, and spectrophotometrically analyzed for API concentration at 221nm.  171 
172 
Results and Discussion 173 
Ibuprofen (IBP) is a weak acid with a pKa of 4.4. The carboxylic group in the chemical 174 
structure is responsible for its pH-dependent solubility. At pH 7, IBP is completely dissolved 175 
after 15 min, whereas, the release at pH 5, 3 and 1 is limited to 57, 40 and 29%, respectively, 176 
after 60min of dissolution testing. The tertiairy amine function in the chemical structure of 177 
Eudragit® E (EudrE) causes its pH-dependent release profiles. In contrast to IBP, a higher pH 178 
reduces the dissolution rate of EudrE. It was therefore appropriate to combine both components 179 
(IBP and EudrE) in one formulation. 180 
The processing of an EudrE mixture containing 30wt.% ibuprofen (IBP) via hot melt 181 
extrusion (HME), followed by injection molding (IM) yielded a transparent formulation, 182 
classified as a glassy solid solution. Thermal analysis revealed a single Tg, located between the 183 
Tg values of the individual components, indicating complete miscibility and compatibility 184 
between drug and polymer (Claeys et al., 2013). Spectroscopic analysis indicated that 185 
electrostatic interactions between the ammonium group of the polymer and the carboxyl group 186 
of IBP (i.e. salt formulation) were responsible for the solubilization of IBP (Claeys et al., 2013). 187 
EudrE is a fast dissolving polymer in acidic media (pH 1 and 3) due to the hydration of the 188 
dimethylamino groups that are fully protonated at this lower pH range, yet it is insoluble in 189 
media with a pH above 5. Chemical modification of the tertiary ammonium group of the 190 
polymer to its quaternized form should allow to determine the minimum amount of positive 191 
charges needed to eliminate this pH-dependent effect, quaternisation of 10, 25, 50 and 75% 192 
were tested.  193 
All polymer samples were analyzed via 1H-nuclear magnetic resonance spectroscopy to 194 
verify the degree of quaternization. Figure 1 illustrates that the decrease of the signal of the 195 
tertiary ammonium group R-N(CH3)2 at ~2.7 ppm is correlated with larger signals of the 196 
quaternary ammonium group R-N+(CH3)3 at ~3.15 ppm. The deviation between the theoretical 197 
calculated and experimental degree of quaternization was 5, 7, 5 and 8% for EudrE-Q10, -Q25, 198 
-Q50 and -Q75, respectively. As the objective was to determine the relative influence of the 199 
degree of quaternization on drug release, these differences were regarded as negligible. 200 
 201 
 202 
Figure 1. 1H-NMR (300 MHz, CD3OD) of EudrE-Quaternized (EudrE-Q) to verify the degree of quaternization 203 
via integration of the signals a and b, representing the signals of the quaternary and tertiary ammonium groups, 204 
respectively.  205 
Second, it was determined whether quaternized Eudragit® E (q-EudrE) samples were 206 
suitable as polymers to solubilize ibuprofen (IBP) upon processing via hot melt extrusion 207 
(HME) and injection molding (IM). As the quaternization of EudrE did not significantly alter 208 
the polymers’ glass transition temperature and a similar drug load (30wt.%) was used, the 209 
processing conditions were chosen similar to the EudrE/IBP 70/30 mixture (Claeys et al., 2013). 210 
All processed formulations with quaternized EudrE (EudrE-Q) as carrier were transparent with 211 
smooth surfaces. Figure 2 illustrates their dissolution behavior in function of pH. At pH 1, all 212 
formulations had similar release characteristics. At pH 3, the protonation rate of the tertiary 213 
ammonium group of EudrE is reduced, resulting in a slower hydration of  the polymer and a 214 
lower IBP release rate compared to pH 1. In contrast, all quaternized EudrE (EudrE-Q) 215 
formulations were not affected by this lower acidic character of the dissolution medium. As a 216 
positive charge is intrinsically present in the chemically modified polymers, the lag phase for 217 
polymer protonation and hydration is avoided, yielding faster release profiles for EudrE-Q 218 
formulations. At pH 5, no IBP was released from the EudrE formulation, while the EudrE-Q10 219 
formulation resulted in a release of 40% after 1h. At pH 5, not all ammonium groups of the 220 
polymer are protonated by the solvent based on their pKa value of 6.1, resulting in insufficient 221 
or no release from the EudrE-Q10- and EudrE-formulations, respectively. Eudr-Q25, -Q50 and 222 
-Q75 formulations, on the other hand, still resulted in fast IBP release profiles as they already 223 
carried sufficient positive charges (due to the high degree of quaternization) and do not rely on 224 
protonation by the solvent to obtain fast drug release. At pH 7, release from all formulations 225 
(EudrE as well as EudrE-Q grades) was slow, indicating that at this pH even a high degree of 226 
quaternisation could not ensure fast hydration of the chemically modified polymethacrylate. 227 
Possibly, the formation of a complex between the positively charged polymer and the negatively 228 
charged IBP also contributed to the incomplete release under these conditions (Kislalioglu et 229 
al., 1991, Jiang et al., 2005). Overall, in vitro dissolution experiments revealed that a minimum 230 
of 25% of quaternization was sufficient to partially (up to pH 5) eliminate the pH-dependent 231 
effect of the EudrE/IBP formulation.  232 
 233 
Figure 2. Release characteristics at different pH-values (1, 3, 5 and 7) of formulations containing 30wt.% 234 
ibuprofen and different polymethacrylate carriers: EudrE (no symbol), EudrE-Q10 (●), EudrE-Q25 (■), EudrE-235 
Q50 (▲), EudrE-Q75 (▼). 236 
As glassy solid solutions are inherently thermodynamically metastable, recrystallization 237 
is inevitable. However, a previous study indicated that the tertiary ammonium group of the 238 
polymer is of high importance as an interaction with the carboxylgroup of IBP (i.e. salt 239 
formation) stabilizes the glassy solid solution for at least 6 months of storage at 25°C and 60% 240 
relative humidity (Claeys et al., 2013). Performing a stability study in similar conditions 241 
revealed the recrystallization of IBP in all formulations containing quaternized EudrE polymers 242 
(EudrE-Q) upon 3 months of storage, irrespective of the amount of quaternization. The 243 
transparent formulations became opaque, an IBP melting endotherm was observed via thermal 244 
analysis and XRD-spectra evidenced clear signs of crystallinity (data not shown). Hence, 245 
quaternization of EudrE, even at a low percentage (i.e. 10%), limits the interactions between 246 
drug and polymers, and reduces the stability of IBP solid solutions upon storage. Possibly the 247 
positive charges of EudrE-Q polymers are obstructing the ability of IBP to release its hydrogen 248 
atom, limiting the possibility for electrostatic interaction with the polymer which is essential 249 
for the stabilization of molecularly dispersed ibuprofen in an Eudragit E matrix. It is also 250 
possible that EudrE-Q polymers, obtained after quaternization in methanol, precipitation in 251 
diethylether, dialysis and lyophilization, still contained some residual solvents. These can alter 252 
the molecular mobility of IBP and increase its tendency to recrystallize.  253 
As protonation of EudrE is responsible for the fast hydration/dissolution of the polymer 254 
and as this protonation is evidently reduced at higher pH values, a second approach to achieve 255 
pH-independent release was to create a low pH micro environment around the tablet during 256 
dissolution via the addition of acids to the HME/IM processed formulations. High 257 
concentrations of acids in the diffusion layer during dissolution could lower the pH, leading to 258 
accelerate protonation of EudrE and enhance the drug release rate. To this end, several 259 
dicarboxylic acids (succinic, glutaric and adipic acid) were added to the formulation  (Table 1). 260 
 The addition of dicarboxylic acids to the IBP/EudrE 30/70 mixture did not influence the 261 
formulation’s ability to form transparent tablets. Dissolution experiments illustrated that the 262 
addition of dicarboyxlic acids did not alter IBP release in a pH 1 and 3 medium (data not 263 
shown), as the dimethyl amino groups of EudrE are already fully protonated. Moreover, the 264 
ability of dicarboxylic acids to release hydrogen atoms is lower at this pH given pKa values of 265 
succinic, glutaric and adipic acid of 4.2, 4.3 and 4.4, respectively. At pH 5, IBP release was 266 
significantly improved (Figure 3) upon the addition of dicarboxylic acids, as the low pH 267 
environment in the diffusion layer around the tablet enhances IBP release rate. This 268 
improvement was concentration driven as higher concentrations of dicarboxylic acids induced 269 
faster drug release. IBP release depended also on the type of dicarboxylic acid: the fastest 270 
release was observed in combination with succinic acid, while adipic acid had less impact. This 271 
could be related to the polarity of the dicarboxylic acids, as succinic acid was the most polar 272 
compound (log P -0.59, vs. -0.29 and 0.08 for glutaric and adipic acid, respectively) (Table 1).  273 
 274 
Figure 3. Release profiles of IBP/EudrE 30/70 mixtures (no symbol) at pH 5 with the addition of 10, 15 and 20% 275 
of adipic (♦), glutaric (■) and succinic acid (●), respectively. 276 
The importance of low pH in the diffusion layer was illustrated by the addition of 20% 277 
disodium succinate to the formulation: IBP release was limited to 10% after 60 min, vs. 92% 278 
in combination with 20% succinic acid (cf: a solution containing 0.1N of succinic acid and 279 
disodium succinate has a pH value of 2.7 and 7, respectively). 280 
Figure 4 illustrates the formulation’s stability at room temperature. The glassy solid 281 
solution tablets containing dicarboxylic acids were mechanical unstable (unable to maintain 282 
their structure). Two underlying reasons were identified: 1. The plasticizing effect of IBP on 283 
EudrE (Claeys et al., 2013). Increasing the dicarboxylic acid concentration also increased the 284 
IBP/EudrE ratio thereby inducing more molecular mobility; and 2. The molecular mobility of 285 
the dicarboxylic acids. Figure 4 and Table 2 illustrates that the formulation’s mechanical 286 
stability was dependent on the length of the dicarboxylic acid (stability of formulation with 287 
succinic > glutaric > adipic). It is known from previous research (Claeys et al., 2013) that the 288 
change of a t-butyl group in the polymer structure to a n-butyl group increases the molecular 289 
mobility of the polymer as a result of an increase in free volume and a less denser polymer 290 
structure. As adipic acid had the highest amount of carbons between its 2 carboxylic groups, 291 
the polymer’s free volume and its molecular mobility were increased to a higher extent 292 
compared to succinic and glutaric acid containing formulations, resulting in a lower mechanical 293 
stability (Table 2).  294 
Table 2. Tablet diameter upon 1 month of storage at 25°C, 60% relative humidity of EudrE/IBP 70/30 with the 295 
addition of 10, 15 and 20% of dicarboxylic acid, respectively. 296 
Dicarboxylic 
acid 
 
 
IBP/EudrE/Acid 
30/70/0 
 
30/60/10 
 
30/55/15 
 
30/50/20 
Succinic  10.0mm 10.2mm 10.4mm 11.9mm 
Glutaric  10.0mm 10.4mm 11.1mm 13.8mm 
Adipic  10.0mm 10.4mm 11.4 14.2mm 
     
 297 
Figure 4. Tablet diameter upon 1 month of storage at 25°C, 60% relative humidity of EudrE/IBP 70/30 (upper 298 
left) with the addition of 20% succinic acid (upper right), glutaric acid (lower left) and adipic acid (lower right), 299 
respectively. 300 
  301 
Conclusion 302 
A pH-independent immediate release polymethacrylate formulation was created via a 303 
chemical modification of the polymer (i.e. quaternisation of amine function) and via the 304 
addition of dicarboxylic acids (succinic, glutaric and adipic acid). The presence of a positively 305 
charged polymer and the low pH micro-environment during dissolution allowed the release of 306 
IBP independent of the solvent pH (up to pH 5). However, the quaternization of the polymer 307 
induced stability issues (recrystallization of API) and the formulations containing dicarboxylic 308 
acids were classified as mechanically unstable. Hence, further research is needed to obtain a 309 
pH-independent immediate release formulation containing EudrE and IBP.  310 
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